---
schema_version: "secwatch.filing_event.v1"
accession: "0001404644-26-000044"
form_type: "8-K"
ticker: "NGNE"
cik: "0001404644"
company_name: "Neurogene Inc."
filed_at: "2026-06-08T11:32:53+00:00"
generated_at: "2026-06-08T11:35:53.854625+00:00"
event_type: "other_material"
sentiment: "positive"
materiality_score: 0.7
calibrated_materiality_score: 0.7
confidence: "high"
source: SEC EDGAR
---

# Neurogene completes dosing in NGN-401 Rett trial; no HLH, topline expected 2H 2027

## Summary
- Dosed 25 participants in Embolden trial (target 20, ITT up to 24) due to strong demand from Rett community.
- NGN-401 generally well-tolerated; no HLH cases at 1E15 vg dose across Phase 1/2 and Embolden (n=35).
- Topline data from registrational trial expected in 2H 2027; BLA submission planned.
- Interim Phase 1/2 data with ≥12-month follow-up for all 10 participants expected mid-2026.

## SEC filing metadata
- accession: 0001404644-26-000044
- form_type: 8-K
- ticker: NGNE
- cik: 0001404644
- company_name: Neurogene Inc.
- filed_at: 2026-06-08T11:32:53+00:00
- event_type: other_material
- sentiment: positive
- materiality_score: 0.7
- calibrated_materiality_score: 0.7
- confidence: high
- sec_items: 7.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1404644/000140464426000044/0001404644-26-000044-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1404644/000140464426000044/ngne-20260608.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001404644-26-000044
- JSON: https://secwatch.observer/filing/0001404644-26-000044.json
- Plain text: https://secwatch.observer/filing/0001404644-26-000044.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.